Bicalutamide Reduces Risk of Prostate Cancer Progression


In men with localized or locally advanced prostate cancer, treatment with the antiandrogen bicalutamide (Casodex; AstraZeneca, Wilmington, Delaware), either alone or as part of a curative regimen, significantly reduces the risk of disease progression, according to a recent report.

The current findings are in agreement with those from a smaller study published last year that linked bicalutamide use with a 43% reduction in the risk of disease progression (see Reuters Health report September 13, 2001). Shortly after the release of these findings, the drug was approved as a treatment for early prostate cancer in the UK (see Reuters Health report September 17, 2001).

However, the benefits of the drug must be weighed against the morbidity of long-term hormonal therapy, study author Dr. William A. See, from the Medical College of Wisconsin in Milwaukee, and colleagues note. Also, longer follow-up is needed to determine if the reduced risk of disease progression translates into a survival benefit.

0 תגובות

השאירו תגובה

רוצה להצטרף לדיון?
תרגישו חופשי לתרום!

כתיבת תגובה

מידע נוסף לעיונך

כתבות בנושאים דומים

© ‫ e-Med
 כל הזכויות שמורות

 

התכנים המוצגים באתר זה מיועדים לאנשי צוות רפואי בלבד

אם כבר נרשמת, יש להקליד את פרטי הזיהוי שלך
עדיין לא נרשמת? באפשרותך לבצע רישום כאן
להרשמה לאתר